One of the most lethal forms of breast cancer has long shrugged off the best drugs in the oncologist’s arsenal, leaving ...

METiS TechBio ("METiS") today announced that two of its oncology pipeline candidates, MTS-105 and MTS-107, have been published in leading international peer-reviewed journals, Nature Communications ...

Researchers at MIT and Stanford University have developed a new way to stimulate the immune system to attack tumor cells. Using molecules known as AbLecs, which consist of a lectin attached to a tumor ...

In 1901, Paul Ehrlich conducted one of the landmark experiments in immunology. While studying the immune response in goats using blood from other animals, ...

An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual ...

Discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and promising trial results ...

In this installment of The OncoloGIST, Hans Lee, MD, director of Myeloma Research at Sarah Cannon Research Institute, ...

Since acquiring exclusive rights to launch and commercialise catumaxomab in 2024, in partnership with Lindis Biotech, Pharmanovia has been committed to ensuring people have access to a treatment that ...

Early-life viral infection programs immune cells to hijack allergy-associated maternal antibodies, driving allergy risk later ...

In 2020, as scientists around the world were racing to understand COVID-19, Prof. Roy Bar-Ziv and his team at the Weizmann ...

A University of Rochester study suggests farm-raised Mennonite babies develop more mature immune responses in their first ...

Although the readout was only from four multiple myeloma patients, attendees at the meeting wondered at how far the CAR T-cell therapy field has come.